Pain Response With Different Therapies for Castration-Resistant Prostate Cancer
Posted: Friday, March 27, 2020
Patients with metastatic castration-resistant prostate cancer experienced greater pain reduction when they received cabazitaxel compared with the androgen-signaling–targeted agents abiraterone or enzalutamide. Although Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, and colleagues found similar trends in health-related quality of life between patients who received cabazitaxel versus abiraterone or enzalutamide, the deterioration in quality-of-life metrics was more rapid among those who received abiraterone or enzalutamide. The findings were presented at the 2020 Genitourinary (GU) Cancers Symposium in San Francisco (Abstract 16).
Using data from the CARD study, in which patients (n = 255) were randomly assigned to receive cabazitaxel or androgen-signaling–targeted agents, the researchers analyzed pain response and health-related quality of life. Pain response was defined as a decrease of more than 30% in pain intensity score without analgesic use. The Functional Assessment of Cancer Therapy–Prostate (FACT-P) questionnaire was used to analyze health-related quality of life.
Of the patients treated with cabazitaxel, 45.9% achieved a pain response versus 19.3% of patients treated with androgen-signaling–targeted agents (P < .0001). The probability of not having pain progression was also higher among patients treated with cabazitaxel; however, health-related quality-of-life reports were similar between the two groups. Improvement in the quality-of-life score from baseline was reported by 27 patients treated with cabazitaxel and 26 patients treated with androgen-signaling–targeted agents. Similarly, quality-of-life scores were maintained or improved for 81 and 86 patients, respectively.
A deterioration in the baseline quality-of-life scores was reported in 22.2% of patients treated with cabazitaxel and 24.6% of those who received androgen-signaling–targeted agents. The median time to deterioration of quality of life was 14.8 months and 8.9 months with cabazitaxel and androgen-signaling–targeted agents, respectively (P = .207).
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
